Evaluating the effectiveness of the universal immunization program against varicella in Japanese children期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Evaluating the effectiveness of the universal immunization program against varicella in Japanese children

Institution:	1. Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan;2. Graduate School of Health Sciences, Fujita Health University, Toyoake, Aichi 470-1192, Japan;3. Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan;1. Division of Pediatric Infectious Diseases, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;2. Department of Social and Preventive Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea;3. National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Republic of Korea;4. Expanded Programme on Immunization Unit, World Health Organization Regional Office for the Western Pacific, Manila, Philippines;5. Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea;6. Center for Healthy Society and Education, Seoul National University College of Medicine, Seoul, Republic of Korea;1. Toyama Dermatologic Clinic, 2-6-7-2 Aburatsu, Nichinan City, Miyazaki 887-0001, Japan;2. Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan;1. Pediatrics, Rathausgasse 1, 79336 Herbolzheim, Germany;2. ASP 7 Ragusa, Dipartimento di Prevenzione, servizio di Epidemiologia e Prevenzione, Via Aldo Licitra 11, 97100, Ragusa, Italy;3. Sanofi Pasteur MSD, 162 Avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France;1. Merck & Co., Inc, Whitehouse Station, NJ, United States;2. Primary Physicians Research, Pittsburgh, PA, United States;3. Cincinnati Children''s Hospital, Cincinnati, OH, United States;1. University Hospital, Hradec Kralove, Czech Republic;2. Department of Vaccines, Norwegian Institute of Public Health, Oslo, Norway;3. Pediatric Highly Intensive Care Unit, University of Milan, Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico, Milan, Italy;4. Swedish Institute for Communicable Disease Control, Stockholm, Sweden;5. Department of Clinical Sciences Pediatrics, Umeå University, Umeå, Sweden;6. University of Medicine and Pharmacy Iuliu Ha?ieganu, Cluj-Napoca, Romania;7. Institute of Immunology, Moscow, Russia;8. Department of Epidemiology, Regional Office of Public Health, Trencín, Slovak Republic;9. Vilnius University, Clinic of Paediatrics, Vilnius, Lithuania;10. University School of Medical Sciences, Poznan, Poland;11. Regional Medical Center for Mother and Child, Poznan, Poland;12. GlaxoSmithKline Vaccines, King of Prussia, PA, USA;13. GlaxoSmithKline Vaccines, Wavre, Belgium

Abstract:	ObjectiveMatched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan.MethodsCases were laboratory confirmed varicella patient under 15 years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2 weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE).ResultsVaricella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval CI]: 58.6–86.9%; P < 0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7–97.6%; P < 0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1–87.3%; P < 0.001) and 94.7% (95% CI: 86.0–98.0%; P < 0.001), respectively.ConclusionsVE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.

Keywords:	Varicella Live attenuated vaccine Vaccine effectiveness Case control study CI"} {"#name":"keyword" "$":{"id":"k0030"} "$$":[{"#name":"text" "_":"confidence interval LAMP"} {"#name":"keyword" "$":{"id":"k0040"} "$$":[{"#name":"text" "_":"loop-mediated isothermal amplification MR"} {"#name":"keyword" "$":{"id":"k0050"} "$$":[{"#name":"text" "_":"measles and rubella PCR"} {"#name":"keyword" "$":{"id":"k0060"} "$$":[{"#name":"text" "_":"polymerase chain reaction VE"} {"#name":"keyword" "$":{"id":"k0070"} "$$":[{"#name":"text" "_":"vaccine effectiveness VZV"} {"#name":"keyword" "$":{"id":"k0080"} "$$":[{"#name":"text" "_":"varicella zoster virus
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏